FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/GILD
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Gilead Sciences, Inc. (GILD) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Gilead Sciences (GILD) trades at $169.04, up 1.29% with bullish technical signals and strong institutional support. The stock shows positive earnings momentum with three consecutive quarterly beats, though 2026 projections indicate a net loss. Recent developments include expanded HIV prevention access agreements in Latin America and advancing oncology pipeline, positioning the company at an inflection point according to management.
While analyst consensus remains strongly bullish (65% buy ratings), investors face mixed fundamentals with negative 2026 profit margins offset by robust cash flow and strategic growth initiatives. Key risks include execution challenges in new therapeutic areas and patent expirations, but current valuation metrics suggest potential upside from the $165.38 consensus target.
Read full analysis

Key Stats

  • Market Cap
    $207.00B
  • Volume
    5,817,788
  • Sector
    Health
  • 52W High
    $174.48
  • 52W Low
    $118.14
  • Typical Hold Time
    115 Days
  • Enterprise Value
    $226.79B
  • Div Yield
    1.97%
  • Trading Activity
    55% Sell | 45% Buy
$169.37
52W Low: $118.14
10 Nov 2025
52W High: $174.48
04 Nov 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $118.14 and a high of $174.48, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Most Recent News

Content is generated by Aura AI

Silvercrest ranks #8 in Nasdaq eVestment Q3 2026 Brand Awareness among mid-sized asset managers

Silvercrest Asset Management Group Inc. was ranked #8 in Nasdaq eVestment’s Q3 2026 Brand Awareness Rankings among mid-sized firms managing $2.5 billion to $40 billion in assets. This ranking reflects strong engagement from consultants and asset owne...

Market News
3 hours ago
Na
Bullish
news icon
Silvercrest ranks #8 in Nasdaq eVestment Q3 2026 Brand Awareness among mid-sized asset managers

New nonprofit Software Safety Institute launches to reduce harm from insecure software.

The Software Safety Institute (SSI), a new independent nonprofit, has launched to tackle preventable harm caused by unsafe and insecure software. SSI aims to improve software safety by changing industry incentives and practices through research, publ...

Market News
3 hours ago
Not Specified
Neutral
New nonprofit Software Safety Institute launches to reduce harm from insecure software.

Kinross Gold investors urged to join class action for losses by Jan 5, 2027 deadline

Hagens Berman law firm has filed a class action lawsuit against Kinross Gold Corporation for alleged securities fraud affecting investors who bought shares between Feb 18, 2022, and Sept 23, 2026. Investors who suffered substantial losses during this...

Market News
5 hours ago
GlobeNewsWire
Bearish
news icon
Kinross Gold investors urged to join class action for losses by Jan 5, 2027 deadline
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $207.00B
  • Volume
    5,817,788
  • Sector
    Health
  • 52W High
    $174.48
  • 52W Low
    $118.14
  • Typical Hold Time
    115 Days
  • Enterprise Value
    $226.79B
  • Div Yield
    1.97%
  • Trading Activity
    55% Sell | 45% Buy
$169.37
52W Low: $118.14
10 Nov 2025
52W High: $174.48
04 Nov 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $118.14 and a high of $174.48, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!